Released Nov 14, 2024, after the close
10-Q filed Nov 14, 2024, 45 days after period end · 0001493152-24-045933
Q2 2025 · 10-Q
Revenue$18.88M$18.88M +33.4% vs Q2 2024+0.4% vs Q1 2025
Net Income-$11.04M-$11.04M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.01-$0.01 N/M vs Q2 2024no prior Q1 2025 on file
Gross Profit$8,197,428+27.1%
Operating Income$3,484,943+81.0%
Operating Cash Flowderived$1,456,844N/M
Free Cash Flowderived$1,364,399—
Margins · derived
Gross margin43.4%−2.1 pt vs Q2 2024
Operating margin18.5%+4.9 pt vs Q2 2024
Net margin-58.5%−163.9 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $18.88M | $14.16M | $8.59M | $8.56M |
| Net Income | -$11.04M | $14.93M | $1.52M | $1.80M |
| EPS Diluted | -$0.01 | $0.01 | $0.00 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR